The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $23,608,247 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 150 grants at over 100 hospitals in 17 countries.




Cincinnati Children's Hospital – $50,000

Amount
$50,000.00
Date
May 2022

Targeting Histone Lysine Demethylases to Treat Diffuse Intrinsic Pontine Glioma

SIOPe DIPG/DMG Registry – $779,018

Amount
$779,018.00
Date
March 2022

Renewal of the European DIPG/DMG Registry

Funding of PBTCF 2022 - $25,000

Amount
$25,000.00
Date
January 2022

Massachusetts General Hospital – $50,000

Amount
$50,000.00
Date
November 2021

Targeted Protein Degradation for DIPG Therapy

CONNECT2007 - $385,794

Amount
$385,794.00
Date
September 2021

Phase I/II Study of Lutathera in Pediatric and Young Adult Patients with Recurrent and/or Progressive High-Grade Central Nervous System (CNS) Tumors and Meningiomas which Express Somatostatin Type 2A Receptors and Demonstrate Uptake on DOTATATE

CONNECT2109A - $705,764

Amount
$705,764.00
Date
September 2021

CONNECT2109A: A molecularly-guided phase II study of ribociclib and everolimus in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG)

CONNECT Consortium - $278,619

Amount
$278,619.00
Date
September 2021

Immuno-Modulation to Treat Poor-Prognosis Pediatric Brain Tumors

Institute of Cancer Research – $113,747

Amount
$113,747.00
Date
September 2021

Co-Culture Disruptor Screens to Target Cell-Cell Interactions in DMG

Institute of Cancer Research – $498,716

Amount
$498,716.00
Date
September 2021

Translating Mechanism to Patient Benefit for ACVR1-Mutant Diffuse Intrinsic Pontine Glioma (DIPG) - An International Connect Consortium Preclinical / Clinical

Sydney Children’s Hospital – $195,327

Amount
$195,327.00
Date
September 2021

Phase I/II Study of Oral DFMO and AMXT1501 for DIPG/DMG

Children’s Hospital of Colorado – $200,000

Amount
$200,000.00
Date
September 2021

Multimodality, Combination Treatment Strategy for DIPG/DMG

Children's Cancer Institute – $50,000

Amount
$50,000.00
Date
September 2021

Developing Novel Combination Therapies for Diffuse Intrinsic Pontine Glioma

Cincinnati Children's Hospital – $200,000

Amount
$200,000.00
Date
September 2021

Targeting Purine Synthesis and One Carbon Metabolism in DIPG

UPMC Children's Hospital – $50,000

Amount
$50,000.00
Date
September 2021

The Role of QPRT and NAD Pathways in DIPG Treatment Resistance

University of Queensland Diamantina Institute – $100,000

Amount
$100,000.00
Date
September 2021

Innovative Models of the Brain Microenvironment to Identify New Treatments for Medulloblastoma